Humacyte (HUMA) News Today $4.64 +1.18 (+34.10%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Humacyte surges on FDA approval for Symvess vascular repair productDecember 21 at 3:21 AM | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $596,000 in Humacyte, Inc. (NASDAQ:HUMA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 109,542 shares of the compaDecember 21 at 3:08 AM | marketbeat.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMADecember 20 at 10:58 PM | globenewswire.comHumacyte Shares Surge 38% on FDA Approval of SymvessDecember 20 at 10:20 PM | marketwatch.comHumacyte’s Symvess Gains FDA Approval and Positions for Market SuccessDecember 20 at 10:20 PM | markets.businessinsider.comHumacyte Stock Hits Over 1-Month Highs On FDA Nod For Bioengineered Tissue In Treating Vascular Trauma, Retail Interest SoarsDecember 20 at 10:20 PM | msn.comHumacyte price target raised to $15 from $12 at H.C. WainwrightDecember 20 at 5:20 PM | markets.businessinsider.comHumacyte stock may fail to sustain today’s gains: find out moreDecember 20 at 5:20 PM | msn.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)December 20 at 1:25 PM | globenewswire.comHumacyte (NASDAQ:HUMA) Shares Gap Up - Here's WhyHumacyte (NASDAQ:HUMA) Shares Gap Up - Here's WhyDecember 20 at 10:37 AM | marketbeat.comHumacyte's (HUMA) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Friday.December 20 at 10:27 AM | marketbeat.comHumacyte's (HUMA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research report on Friday.December 20 at 8:31 AM | marketbeat.comWhy Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?December 20 at 8:15 AM | benzinga.comShareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreDecember 20 at 5:45 AM | prnewswire.comHumacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular TraumaDecember 19 at 10:47 PM | globenewswire.comHUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the FirmDecember 19 at 9:00 PM | globenewswire.comHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 19 at 4:00 PM | globenewswire.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitDecember 19 at 1:26 PM | prnewswire.comHumacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens BermanDecember 19 at 1:24 PM | globenewswire.comLevi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – HUMADecember 19 at 12:09 PM | globenewswire.comHumacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More InformationDecember 19 at 10:55 AM | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by BrokeragesShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a sDecember 19 at 6:35 AM | marketbeat.comInvestors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMADecember 19 at 5:45 AM | prnewswire.comHumacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens BermanDecember 18 at 8:28 PM | markets.businessinsider.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitDecember 18 at 8:10 PM | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit – HUMADecember 18 at 1:34 PM | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of HumacyteDecember 18 at 10:04 AM | prnewswire.comHUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the FirmDecember 17, 2024 | globenewswire.comROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMADecember 17, 2024 | globenewswire.comHumacyte (NASDAQ:HUMA) Stock Price Down 6.7% - Time to Sell?Humacyte (NASDAQ:HUMA) Stock Price Down 6.7% - Here's What HappenedDecember 17, 2024 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest UpdateHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 20,330,000 shares, an increase of 6.2% from the November 15th total of 19,140,000 shares. Based on an average daily volume of 3,040,000 shares, the days-to-cover ratio is presently 6.7 days. Currently, 19.6% of the company's stock are sold short.December 17, 2024 | marketbeat.comContact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA)December 17, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMADecember 16, 2024 | investing.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitDecember 16, 2024 | prnewswire.comHumacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens BermanDecember 16, 2024 | globenewswire.comInvestors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMADecember 16, 2024 | globenewswire.comHumacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January ...December 16, 2024 | gurufocus.comHumacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMADecember 16, 2024 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMADecember 15, 2024 | investing.comROSEN, NATIONAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMADecember 14, 2024 | investing.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Humacyte, Inc. ...December 14, 2024 | gurufocus.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMADecember 14, 2024 | globenewswire.comHUMA INVESTOR ALERT: Kirby McInerney LLP Notifies Humacyte, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitDecember 14, 2024 | markets.businessinsider.comHumacyte: FDA Waiting Game Bleeding Company DryDecember 14, 2024 | seekingalpha.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitDecember 13, 2024 | prnewswire.comHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. ...December 13, 2024 | gurufocus.comHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 13, 2024 | globenewswire.comLevi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMADecember 13, 2024 | prnewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)December 12, 2024 | globenewswire.comHumacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens BermanDecember 12, 2024 | globenewswire.com Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.170.61▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼458▲HUMA Articles Average Week Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies APGE News Today IBRX News Today WVE News Today MIRM News Today AKRO News Today TARS News Today AMPH News Today IRON News Today CGON News Today HRMY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts